Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed ...

Starting today, pharmacies can no longer make cheaper alternatives to popular weight loss drugs, driving up costs for ...

A revolution in weight loss treatment may soon be on the way — and it doesn’t involve a needle. Eli Lilly, the pharmaceutical ...

1️⃣ ‘Summer of hell’: What’s typically a key money-making time for airlines could fall short this year. Fears about flying, ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk, the company that makes Wegovy and Ozempic, is abruptly ousting its chief executive over concerns the firm is losing ground in the popular weight-loss drug market. The firm's market value ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...